Piper Sandler analyst Adam Maeder raised the firm’s price target on ResMed (RMD) to $270 from $248 and keeps a Neutral rating on the shares. The firm notes the company reported Q4 results that beat estimates on the top-line and bottom-line. Altogether, Piper views this as a solid quarterly update from ResMed led by the gross margin performance with U.S. devices the one soft spot. However, the firm elects to stay on the sidelines for the time being.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: